/NBSE
NBSE Stock - NeuBase Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.38-1.56%
$0.01 (-1.56%) • May 10
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.42
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NBSE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.37 – $0.38
TARGET (TP)$0.43
STOP LOSS$0.35
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.94
52W High$4.44
52W Low$0.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,262,512 | $-575,521 | $-280,463 | $-128,372 | $-13,903,955 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-33,318,339 | $-26,565,447 | $-17,069,306 | $-26,336,407 | $-13,903,955 |
| Net Income | $-34,234,561 | $-25,667,406 | $-17,261,253 | $-27,087,198 | $-13,236,900 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-21.08 | $-18.80 | $-17.60 | $-65.49 | $-93.57 |
Company Overview
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NBSEBeat Rate
53%
Last 17 quarters
Avg Surprise
-32.6%
EPS vs Estimate
Beats / Misses
9/7
1 met exactly
Latest EPS
$-0.95
Q4 2023
EPS Surprise History
Q1 22
+4.0%
$-4.80vs$-5.00
Q2 22
-15.4%
$-6.00vs$-5.20
Q3 22
+13.3%
$-5.20vs$-6.00
Q4 22
+11.1%
$-4.80vs$-5.40
Q1 23
-18.2%
$-2.60vs$-2.20
Q2 23
-20.0%
$-2.40vs$-2.00
Q3 23
+30.0%
$-1.26vs$-1.80
Q4 23
+47.8%
$-0.95vs$-1.82
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Feb 13, 2024 | $-0.97 | — | — | — |
Q4 2023 | Nov 9, 2023 | $-1.82 | $-0.95 | +47.8% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-1.80 | $-1.26 | +30.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-2.00 | $-2.40 | -20.0% | ✗ MISS |
Q1 2023 | Feb 14, 2023 | $-2.20 | $-2.60 | -18.2% | ✗ MISS |
Q4 2022 | Dec 21, 2022 | $-5.40 | $-4.80 | +11.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-6.00 | $-5.20 | +13.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-5.20 | $-6.00 | -15.4% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-5.00 | $-4.80 | +4.0% | ✓ BEAT |
Q4 2021 | Dec 23, 2021 | $-5.40 | $-4.20 | +22.2% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-4.80 | $-5.80 | -20.8% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-4.60 | $-4.80 | -4.3% | ✗ MISS |
Q1 2021 | Feb 11, 2021 | $-4.80 | $-3.60 | +25.0% | ✓ BEAT |
Q4 2020 | Dec 23, 2020 | $-4.00 | $-4.00 | 0.0% | = MET |
Q3 2020 | Aug 13, 2020 | $-4.80 | $-3.60 | +25.0% | ✓ BEAT |
Q2 2020 | May 14, 2020 | $-4.40 | $-5.20 | -18.2% | ✗ MISS |
Q1 2020 | Mar 26, 2020 | $-7.20 | $-5.20 | +27.8% | ✓ BEAT |
Q1 2020 | Jan 10, 2020 | $-0.28 | $-2.14 | -664.3% | ✗ MISS |
Q3 2019 | Aug 14, 2019 | — | $-8.00 | — | — |
Q2 2019 | May 15, 2019 | — | $-8.08 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NBSE
What is NBSE's current stock price?
NeuBase Therapeutics, Inc. (NBSE) is currently trading at $0.38 per share. The stock has moved -1.56% today.
What is the analyst price target for NBSE?
No analyst price targets are currently available for this stock.
What sector is NeuBase Therapeutics, Inc. in?
NeuBase Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NBSE's market cap?
NeuBase Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does NBSE pay dividends?
No, NeuBase Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASLN
ASLAN Pharmaceuticals Limited
$0.60
Mkt Cap: $0.2B
CWBR
CohBar, Inc.
$0.41
Mkt Cap: $0.0B
CYTO
Altamira Therapeutics Ltd.
$0.30
Mkt Cap: $0.0B
IMPL
Impel Pharmaceuticals Inc.
$0.04
Mkt Cap: $0.0B
NMTRQ
9 Meters Biopharma, Inc.
$0.00
Mkt Cap: $0.0B
ONCSQ
OncoSec Medical Incorporated
$0.00
Mkt Cap: $0.0B
ONCT
Oncternal Therapeutics, Inc.
$0.53
Mkt Cap: $0.0B
SAVAW
Cassava Sciences, Inc. Warrant
$0.03
Mkt Cap: $0.0B
TMBR
Timber Pharmaceuticals, Inc.
$0.34
Mkt Cap: $0.0B
VBIV
VBI Vaccines Inc.
$0.07
Mkt Cap: $0.0B
Explore stocks similar to NBSE for comparison